Saliva of patients affected by salivary gland tumour: An NMR metabolomics analysis

Publication date: Available online 9 August 2018Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Manuela Grimaldi, Angelica Palisi, Giuseppina Rossi, Ilaria Stillitano, Francesco Faiella, Paola Montoro, Manuela Rodriquez, Remo Palladino, Anna Maria D’Ursi, Rocco RomanoAbstractCancers affecting the salivary glands have been an increasing incidence. Salivary gland cancer is not detected until it reaches an advanced stage, which would generally result in a poor prognosis and survival rate. Therefore, early detection as well as the screening of high risk populations with precancerous lesions remains an unmet medical need.In the present work, we present a NMR-based metabolomic study of the saliva of patients suffering from salivary gland tumours. Analysis of data was done using a combined approach based on PRICONA quantitative analysis and statistical multivariate analysis. Interestingly, both the analytical methods indicate that individuals affected by parotid tumour have a characteristic metabolomic profile characterized by abnormalities in the concentration of several aminoacids. Among these the most significant are those relative to Alanine and Leucine suggestive of an alteration in the metabolic pathways of glycogenic aminoacids and ketone bodies. Our data, describing the preliminary metabolomics fingerprint of parotid tumour, are consistent with the recent view that oncogenic signalling corresponds to alteration in the metabolism of nutrient pull (Va...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research

Related Links:

CONCLUSION: A favorable response of HER2-positive salivary gland carcinomas to an antibody-drug conjugate could be shown. Furthermore, no convincing data regarding response to programmed cell death protein 1 (PD1)/programmed death ligand 1 (PD-L1) inhibitors in advanced salivary gland cancer were presented. Further studies and ideas for new treatment approaches will be needed to improve the therapeutic options for patients with salivary gland carcinoma. PMID: 31628530 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Salivary gland cancer (SGC) is a distinct but heterogeneous group of malignancies comprising approximately 6.5% of cases within head and neck cancer [1]. This makes it a rare cancer, with an estimated age-standardized annual incidence of less than 2/100.000 in most countries [2]. The most recent World Health Organization classification of Head and Neck Tumours distinguishes 22 histopathological subtypes of SGC, which makes each subtype even rarer [3]. Recognition of, and differentiation between these different subtypes is notoriously difficult and different subtypes exhibit different clinical features adding up to the comp...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Tumour Review Source Type: research
ConclusionsWe are the first that have successfully developed and characterized long-term organoid cultures for ACC and SDC. These organoid cell lines will facilitate pre-clinical and pharmacological studies. Other SGC organoid cultures do not grow infinitely, but do provide an in vitro model to study different treatments during initial growth.Legal entity responsible for the studyRadboud University Medical Center.FundingDutch Salivary Gland Cancer Patient Platform.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsLNR classification should be considered as a complementary system to TNM staging and LNR classification based clinical trials deserve further research.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
In conclusion, our data showed that pan-Trk IHC is a reasonable screening test for diagnosing secretory carcinoma of the salivary gland.
Source: Virchows Archiv - Category: Pathology Source Type: research
In this study, we added 11 years of follow-up (1958-2009), used improved radiation dose estimates, considered effects of smoking and alcohol consumption and performed dose-response analyses by anatomical sub-site. In examining 52 years'worth of data, we ascertained the occurrence of 394 oral cavity/pharyngeal cancers, 486 esophageal cancers and 5,661 stomach cancers among 105,444 subjects. The radiation risk for oral cavity/pharyngeal cancer, other than salivary gland, was elevated but not significantly so. In contrast, salivary gland cancer exhibited a strong linear dose response with excess relative risk (ERR) of 2.54 pe...
Source: Radiation Research - Category: Physics Authors: Tags: Radiat Res Source Type: research
Myoepithelial carcinoma (MEC) is an extremely rare salivary gland malignancy accounting for 1% of all salivary gland cancers [1 –4]. MEC has long been reported as a low grade malignancy with indolent clinical behaviour and good long-term survival [5]. These tumours have been reported to arise from a number of organs viz. major and minor salivary gland, breast, airway, etc [1,6,7]. Irrespective of sub-site, surgical resecti on is considered as corner stone of therapy. Even after surgical resection recurrence has been reported, and this highlights an aggressive group of MEC and a plausible benefit of adjuvant therapy.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Systematic Review Source Type: research
Abstract Although salivary gland cancers comprise only ∼3-6% of head and neck cancers, treatment options for patients with advanced-stage disease are limited. Because of their rarity, salivary gland malignancies are understudied compared to other exocrine tissue cancers. The comparative lack of progress in this cancer field is particularly evident when it comes to our incomplete understanding of the key molecular signals that are causal for the development and/or progression of salivary gland cancers. Using a novel conditional transgenic mouse (K5:RANKL), we demonstrate that Receptor Activator of NFkB Ligand (...
Source: Cytokine - Category: Molecular Biology Authors: Tags: Cytokine Source Type: research
Conclusions: TLG on restaging FDG-PET predicted PFS and OS in patients with RSGC; patients with predicted poor outcome may benefit from alternate, escalated treatment strategies. Multivariate analysis of clinicopathological and imaging parametersParameterPFS HR (95.0% CI)PFS p-valueOS HR (95.0% CI)OS p-valueHistologic subtype, Adenocarcinoma vs. Non-adenocarcinoma2.27 (1.33- 3.89)0.0031.60 (0.91-2.80)0.09TMTV1.01 (0.99-1.012)0.081.00 (1.00-1.011)0.14TLG1.00 (1.00-1.001)
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Head and Neck Posters Source Type: research
Nicole Gibbs, 26, was at a routine dentist's appointment last month when the doctor spotted a growth on the roof her mouth, which was soon discovered to be salivary gland cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Nutrition | Salivary Gland Cancer | Statistics | Study